• 23 September 2015
    CoMO Meets with Local MEP

    On the morning of Friday 18th September 2015 we took the short journey from our new CoMO HQ offices in Bristol to visit our local MEP in Gloucester, Julie Girling. We were so pleased to be able to meet and talk with Julie and we were delighted that she was in favour of our current European project the ‘life-course immunisation initiative’.

    Read More
  • 17 September 2015
    The Cost of Meningitis

    Did you know that, globally, every year more than 1.7 million people contract meningitis? Bacterial meningitis and septicaemia are the most severe forms of the disease…and we mean severe.

    Read More
  • 09 September 2015
    The Meningococcal B Vaccine Debate

    The new meningococcal B vaccine has been licensed in many jurisdictions in the past 2 years. Since 2014, national health authorities have implemented regionally focused campaigns to respond to either outbreaks of Men B invasive disease (e.g. In 2 American Universities) or durable high incidence of Men B disease in some counties (e.g. Quebec hyper-endemic regions). As of September 2015, more than 100,000 doses of the Men B vaccine have been administered - surveillance has confirmed the safety profile and vaccine acceptance in targeted populations has been high. The control of the outbreaks, with large reductions in the incidence of Men B disease, suggests the vaccine is effective against Men B. It is too early to know the duration of protection afforded for those vaccinated.

    Read More